Can MetLife's Earnings Finally Convince the Market It Isn't Just Along for the Ride?

MetLife reports first-quarter 2026 earnings after the close on May 6, 2026, with Wall Street expecting $2.25 per share on revenue of approximately $19.29 billion. The release comes as the life insurance giant navigates a shifting interest rate environment and seeks to demonstrate momentum in its group benefits and retirement solutions businesses. With analysts projecting 14.80% year-over-year EPS growth and the stock trading near its 52-week high, investors will scrutinize whether MetLife can sustain its recent operational momentum and capital return trajectory.

Part 1: Earnings Preview

MetLife, Inc. is one of the world's leading financial services companies, providing insurance, annuities, employee benefits, and asset management to individual and institutional customers in more than 40 countries. Established in 1868, the company generates significant revenue from life insurance, group benefits, and retirement & income solutions, with a market capitalization of approximately $51 billion. The company is particularly well-known for its robust life insurance operations and workplace benefits distributed through employer-sponsored programs.

MetLife will report Q1 2026 results after the close on Wednesday, May 6, with analysts expecting $2.25 per share and revenue of $19.29 billion. The company most recently reported Q4 2025 earnings of $2.58 per share, beating estimates by 9.32% and marking a strong finish to the prior fiscal year. The consensus estimate of $2.25 represents 14.80% growth versus the $1.96 reported in Q1 2025, reflecting expectations for improved underwriting margins and investment income.

Three key themes define this earnings story:

Investment Yield Environment: With interest rates stabilizing after a period of volatility, investors will focus on net investment income trends and whether MetLife is capturing higher yields on its fixed-income portfolio. Management commentary on investment yields and asset allocation will be critical, as this directly impacts profitability across all segments. Analysts expect the company to benefit from reinvestment at more attractive rates, but the pace of improvement remains uncertain.

Group Benefits Growth & Persistency: The group benefits segment—covering employer-sponsored life, dental, and disability insurance—has been a growth driver, and investors will watch for premium growth, underwriting margins, and policy retention (persistency rates). Strong employment levels and corporate demand for voluntary benefits should support top-line growth, but pricing discipline and claims experience will determine margin quality. Any commentary on large case wins or losses will move the stock.

Capital Deployment & Shareholder Returns: MetLife has been an active capital returner through dividends and share repurchases, and investors will scrutinize management's updated capital deployment plans. With book value per share growing and return on equity (ROE) improving, the market expects continued buyback activity and potentially dividend increases. Regulatory capital ratios and management's appetite for M&A versus organic growth will also be in focus.

Leading analysts have generally reconfirmed estimates over the past 30 days, suggesting confidence in the company's ability to meet expectations. However, the stock has missed Wall Street's revenue estimates multiple times over the last two years, adding pressure on management to deliver a clean beat. Analysts at Morgan Stanley and Bank of America have recently trimmed price targets but maintained overweight ratings, citing valuation support and capital return visibility. The consensus view is that MetLife is well-positioned to benefit from higher rates and operational efficiency gains, but execution on group benefits and international expansion will be key to sustaining the growth narrative.

Part 2: Historical Earnings Performance

MetLife has delivered a mixed earnings track record over the past four quarters, with two beats and two misses against analyst estimates. In Q4 2025 (December), the company reported $2.58 per share, beating the $2.36 estimate by 9.32%—the strongest surprise in the recent period. However, Q3 2025 (September) saw a modest beat of 0.43% with $2.34 versus $2.33 expected, while Q2 2025 (June) disappointed with $2.02 against a $2.19 estimate, a -7.76% miss. Q1 2025 (March) also came in light at $1.96 versus $1.99, a -1.51% shortfall.

The pattern reveals improving momentum in the second half of 2025, with the company returning to form after mid-year weakness. The Q4 beat was particularly significant, suggesting operational improvements and better-than-expected investment income as the year closed. However, the two misses in the first half of the year—particularly the -7.76% shortfall in Q2—highlight execution risk and sensitivity to claims experience and market conditions. Investors will be watching closely to see if the Q1 2026 report can sustain the positive trajectory established in Q4, or if the company reverts to the inconsistency seen earlier in 2025. The 14.80% year-over-year growth embedded in the current estimate suggests analysts expect a return to stronger fundamentals, but the recent history of revenue misses adds caution.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

MetLife typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

MetLife's post-earnings price behavior shows moderate volatility, with an average absolute Day 0 move of 0.92% and a Day +1 move of 2.65%. The Day +1 reaction is notably larger, reflecting the market's tendency to digest results overnight and respond more decisively in the following session. The most recent earnings on February 4, 2026 saw a +1.44% Day 0 move followed by a -3.45% Day +1 decline, despite the company beating estimates—suggesting profit-taking or concerns about forward guidance. The November 5, 2025 report produced a -3.44% Day +1 drop on a -0.98% Day 0 move, while August 6, 2025 saw a +1.42% Day 0 gain followed by a -2.80% Day +1 pullback.

The data reveals a consistent pattern of Day +1 selling pressure across the last eight quarters, with six of eight reports producing negative Day +1 moves. The average Day +1 range of 5.33% indicates meaningful intraday volatility, giving active traders opportunities but also risk. Investors should expect a 2–3% move in either direction following the May 6 release, with historical precedent suggesting a bias toward downside follow-through even on beats. The October 30, 2024 report stands out with a -5.72% Day +1 decline, the largest in the dataset, highlighting the potential for outsized moves if results or guidance disappoint.

Part 2.2: Options Market Expected Move

The options market is pricing a 5.27% expected move through the May 15 expiration, implying a range of $75.69 to $84.11. This is nearly double the stock's average historical Day +1 move of 2.65% and aligns more closely with the 5.33% average Day +1 range, suggesting options traders are anticipating above-average volatility for this release. The elevated implied move may reflect uncertainty around guidance or macro factors, and positions the options market as pricing in a more dramatic reaction than the typical post-earnings pattern would suggest.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on MetLife heading into earnings, with a consensus rating of 4.21 out of 5.0 (solidly in Buy territory) and an average price target of $90.25. The target implies 12.9% upside from the current price of $79.90, reflecting confidence in the company's earnings trajectory and capital return potential. The breakdown shows 11 Strong Buy ratings, 1 Moderate Buy, and 7 Hold ratings, with zero Sell or Strong Sell recommendations—a notably positive distribution that underscores Wall Street's constructive view.

Sentiment has remained unchanged over the past month, with the rating count and average recommendation holding steady at 4.21. This stability suggests analysts are comfortable with their current positioning and are awaiting the Q1 results before making further adjustments. The price target range spans $78.00 to $102.00, with the high-end estimate implying 27.7% upside—a reflection of the bull case centered on sustained ROE improvement, higher investment yields, and aggressive capital deployment.

Recent analyst activity has been measured, with firms like Morgan Stanley and Bank of America trimming targets modestly (from $101 to $93 and $103 to $99, respectively) while maintaining Overweight ratings. The adjustments reflect near-term caution around valuation and macro uncertainty, but the maintained Buy ratings signal confidence in the medium-term story. Barclays also reduced its target from $92 to $89 but kept an Overweight rating, citing solid fundamentals offset by sector-wide multiple compression. The consensus view is that MetLife offers attractive risk-reward at current levels, with the earnings report serving as a potential catalyst to close the gap to the $90.25 target if execution is clean.

Part 4: Technical Picture

MetLife enters earnings with strengthening technical momentum, as the Barchart Technical Opinion has shifted from a Sell signal at 88% one month ago to a Buy signal at 24% currently. The signal improved further over the past week, moving from 8% Buy to 24% Buy, indicating a rapid reversal in short-term sentiment. This turnaround reflects the stock's recent rally above key moving averages and suggests technical buyers are re-engaging ahead of the release.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is positive but not yet at extreme levels, leaving room for further upside if earnings impress.
• Medium-term (50% Sell): Neutral-to-bearish reading suggests some consolidation or resistance in the intermediate timeframe, reflecting the stock's recent volatility.
• Long-term (50% Buy): Moderate buy signal reflects constructive longer-term trend structure, consistent with the stock's recovery from mid-2025 lows.

Trend Characteristics: The signal strength is rated as Minimum and the direction is Weakening, suggesting the recent technical improvement is fragile and could reverse quickly if earnings disappoint—investors should view the setup as cautiously constructive rather than robustly bullish.

The stock is trading at $79.90, above all major moving averages: the 5-day ($79.63), 10-day ($78.48), 20-day ($77.35), 50-day ($73.44), 100-day ($76.15), and 200-day ($77.40). This alignment is a bullish technical signal, indicating the stock has reclaimed its trend structure after a period of weakness. The 50-day moving average at $73.44 now serves as a key support level, while the recent breakout above the 200-day at $77.40 suggests the longer-term trend has turned positive.

The stock's position above all major moving averages and the recent shift to a Buy signal provide a supportive technical backdrop heading into earnings, but the "Minimum" strength rating and "Weakening" direction suggest the setup is not robust. The 5.27% options-implied move through May 15 indicates traders are pricing in above-average volatility, and the stock's proximity to recent highs leaves limited cushion for disappointment. Key resistance likely sits near $84, the upper end of the options expected range, while support is anchored at the 50-day moving average around $73.44. Overall, the technical picture is cautiously constructive—favorable for a beat-and-raise scenario, but vulnerable to sharp downside if results or guidance fall short.